التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Exact Sciences Corp
Closed
Sector Healthcare
53.02 0.57
Overview
Share price change
24h
Min
51.96
Max
53.98
Income | -22M -38M |
|---|---|
Sales | 9.7M 709M |
EPS | -0.21 |
Profit margin | -5.393 |
Employees | 6,500 |
EBITDA | -837K 34M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +36.62 upside |
Next Earnings | ١٩ فبراير ٢٠٢٥ |
|---|
Market Cap | -3.4B 9.2B |
|---|---|
Previous open | 52.45 |
Previous close | 53.02 |
News Sentiment
By Acuity
50%
50%
179 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Exact Sciences Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Exact Sciences Corp Forecast
Price Target
By TipRanks
36.62% upside
12 Months Forecast
Average 72 USD 36.62%
High 90 USD
Low 60 USD
Based on 19 Wall Street analysts offering 12 month price targets forExact Sciences Corp - Dist in the last 3 months.
Sentiment
By Acuity
179 / 392 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Exact Sciences Corp
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.
